TRCT
PMCB icon

Tower Research Capital (TRC)’s PharmaCyte Biotech PMCB Stock Holding History

Tower Research Capital (TRC)’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76K Sell
4,888
-1
-0% -$1 ﹤0.01% 4475
2026
Q1 		$3.25K Sell
4,889
-9
-0.2% -$7 ﹤0.01% 4344
2025
Q4 		$3.55K Sell
4,898
-653
-12% -$588 ﹤0.01% 4355
2025
Q3 		$5.38K Buy
5,551
+2,766
+99% +$2.76K ﹤0.01% 4239
2025
Q2 		$3.04K Sell
2,785
-653
-19% -$728 ﹤0.01% 4562
2025
Q1 		$4.3K Buy
3,438
+993
+41% +$1.61K ﹤0.01% 4278
2024
Q4 		$3.84K Sell
2,445
-415
-15% -$716 ﹤0.01% 4575
2024
Q3 		$5.46K Sell
2,860
-4,524
-61% -$8.43K ﹤0.01% 4269
2024
Q2 		$14.5K Buy
7,384
+4,155
+129% +$8.95K ﹤0.01% 3947
2024
Q1 		$7.65K Buy
3,229
+1,354
+72% +$2.93K ﹤0.01% 4174
2023
Q4 		$4.05K Buy
1,875
+657
+54% +$1.42K ﹤0.01% 5001
2023
Q3 		$2.56K Buy
+1,218
New +$3.11K ﹤0.01% 5135
2023
Q2 		– Sell
-505
Closed -$1K – 6290
2023
Q1 		$1K Buy
505
+298
+144% +$876 ﹤0.01% 5594
2022
Q4 		$1K Buy
207
+110
+113% +$315 ﹤0.01% 5649
2022
Q3 		$0 Sell
97
-1,064
-92% -$2.69K ﹤0.01% 6391
2022
Q2 		$2K Buy
+1,161
New +$2.54K ﹤0.01% 5584
2022
Q1 		– Sell
-650
Closed -$2K – 6451
2021
Q4 		$2K Sell
650
-6,420
-91% -$17.7K ﹤0.01% 5651
2021
Q3 		$22K Buy
+7,070
New +$24.9K ﹤0.01% 3638

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Tower Research Capital (TRC)'s PMCB Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its PharmaCyte Biotech (PMCB) stake by 0.02% in Q2 2026, selling an estimated $1 and leaving 4,888 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4475.

Tower Research Capital (TRC) first reported a position in PMCB in Q3 2021 and has held it in 18 quarters since. The position peaked at $22K in Q3 2021. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Tower Research Capital (TRC) held 4,888 shares of PharmaCyte Biotech worth $3.76K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1 PharmaCyte Biotech share in Q2 2026, an estimated $1.
  • PharmaCyte Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4475 holding.
  • Tower Research Capital (TRC) first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s PharmaCyte Biotech position peaked at $22K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.